These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22203543)

  • 41. Controversies in PSA screening.
    O'Sullivan J
    Evid Based Med; 2017 Dec; 22(6):198. PubMed ID: 29122825
    [No Abstract]   [Full Text] [Related]  

  • 42. Narrative vs evidence-based medicine--and, not or.
    Meisel ZF; Karlawish J
    JAMA; 2011 Nov; 306(18):2022-3. PubMed ID: 22068995
    [No Abstract]   [Full Text] [Related]  

  • 43. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 44. Recommendations on use of prostate-specific antigen for prostate cancer screening.
    Garnick MB
    JAMA; 2012 Apr; 307(13):1372; author reply 1372-4. PubMed ID: 22474197
    [No Abstract]   [Full Text] [Related]  

  • 45. Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force.
    Am J Prev Med; 1994; 10(4):187-93. PubMed ID: 7528518
    [No Abstract]   [Full Text] [Related]  

  • 46. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical practice. Screening for prostate cancer.
    Hoffman RM
    N Engl J Med; 2011 Nov; 365(21):2013-9. PubMed ID: 22029754
    [No Abstract]   [Full Text] [Related]  

  • 48. ERSPC and PLCO prostate cancer screening studies: what are the differences?
    Schröder FH; Roobol MJ
    Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
    [No Abstract]   [Full Text] [Related]  

  • 49. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.
    Messing EM; Albertsen P; Andriole GL; Carroll PR; Klein EA
    Urol Oncol; 2012; 30(1):117-9. PubMed ID: 22243597
    [No Abstract]   [Full Text] [Related]  

  • 50. Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Ann Intern Med; 2013 May; 158(10):I-28. PubMed ID: 23567761
    [No Abstract]   [Full Text] [Related]  

  • 51. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
    Makovey I; Stephenson AJ; Haywood S
    Curr Urol Rep; 2013 Jun; 14(3):168-73. PubMed ID: 23568623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 53. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
    Mian BM
    Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
    [No Abstract]   [Full Text] [Related]  

  • 54. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.
    Ciatto S; Zappa M; Villers A; Paez A; Otto SJ; Auvinen A
    BJU Int; 2003 Dec; 92 Suppl 2():97-100. PubMed ID: 14983964
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    Shteynshlyuger A; Andriole GL
    J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Making an informed choice about PSA screening.
    Ward J; Gattellari M
    Aust Fam Physician; 2001 Jul; 30(7):715-6. PubMed ID: 11558209
    [No Abstract]   [Full Text] [Related]  

  • 58. What patients should be told before agreeing to a blood test that could change their lives.
    Talcott JA
    Urology; 2003 Jan; 61(1):7-9. PubMed ID: 12559254
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 60. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.
    Wilt TJ; Scardino PT; Carlsson SV; Basch E
    J Natl Cancer Inst; 2014 Mar; 106(3):dju010. PubMed ID: 24594482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.